Infliximab (Monograph)
Brand names: Avsola, Inflectra, Remicade, Renflexis, Zymfentra
Drug class: Tumor Necrosis Factor Inhibitors, Miscellaneous
Warning
- Serious Infections
-
Increased risk of serious infections that may require hospitalization or result in death, particularly in patients receiving other immunosuppressive agents concomitantly; tuberculosis (frequently disseminated or extrapulmonary), invasive fungal infections (may be disseminated), bacterial (e.g., legionellosis, listeriosis) and viral infections, and other opportunistic infections reported.1 72 155 159 167 194 195 225
-
Carefully consider risks and benefits prior to initiating therapy in patients with chronic or recurring infections.1 159 167 194 195 225
-
Evaluate patients for latent tuberculosis infection prior to and periodically during therapy; if indicated, initiate appropriate antimycobacterial regimen prior to initiating infliximab therapy.1 72 118 159 167 194 195 225
-
Closely monitor patients for infection, including active tuberculosis, in those with a negative tuberculin skin test during and after treatment.1 167 194 195 Discontinue infliximab if serious infection or sepsis occurs.1 34 35 44 118 167 194 195 225 Consider empiric antifungal therapy if serious systemic illness occurs in a patient at risk for invasive fungal infections.1 155 159 167 194 195 225 Serologic tests for histoplasmosis may be negative.1 167 194 195 225
- Malignancy
-
Lymphoma and other malignancies (some fatal) reported in children and adolescents receiving TNF blocking agents.1 154 160 167 194 195 225
-
Aggressive, usually fatal hepatosplenic T-cell lymphoma reported mainly in adolescent and young adult males with Crohn disease or ulcerative colitis receiving TNF blocking agents, including infliximab.1 154 160 167 194 195 225 Most patients received a combination of immunosuppressive agents, including TNF blocking agents and thiopurine analogs (azathioprine or mercaptopurine).1 154 160 167 194 195 225
Introduction
Biologic response modifiers and disease-modifying antirheumatic drugs (DMARDs); chimeric human-murine monoclonal antibodies that block the biologic activity of tumor necrosis factor (TNF, TNF-α).1 7 20 24 167 173 174 175 176 177 194 195 225
Infliximab-abda, infliximab-axxq, and infliximab-dyyb are biosimilars to infliximab (Remicade).167 194 195 A biosimilar is a biological that is highly similar to an FDA-licensed reference biological with the exception of minor differences in clinically inactive components and for which there are no clinically meaningful differences in safety, purity, or potency.170 171 Biosimilars are approved through an abbreviated licensure pathway that establishes biosimilarity between proposed biological and reference biological but does not independently establish safety and effectiveness of the proposed biological.171 In order to be considered an interchangeable biosimilar, a biological product must meet additional requirements beyond demonstrating biosimilarity to its reference product.169 None of the currently available infliximab biosimilars have interchangeable data at this time.172
In this monograph, unless otherwise stated, the term “infliximab products” refers to infliximab (the reference drug) and its biosimilars (infliximab-abda, infliximab-axxq, infliximab-dyyb).
Related/similar drugs
Remicade, Lialda, Simponi, Mavenclad, Entyvio, Bimzelx, Otezla
Uses for Infliximab
Several infliximab biosimilars are available.167 172 194 195 Biosimilarity of these products has been demonstrated for the indications described in the table below (see Table 1 ).167 172 194 195
A sub-Q version of infliximab-dyyb (Zymfentra) is also available for the maintenance treatment of ulcerative colitis and Crohn disease in adults following treatment with IV infliximab.225
FDA-labeled indication |
Infliximab-axxq (Avsola) |
Infliximab-dyyb (Inflectra) |
Infliximab-abda (Renflexis) |
---|---|---|---|
Crohn disease in adults |
X |
X |
X |
Pediatric Crohn disease |
X |
X |
X |
Ulcerative colitis |
X |
X |
X |
Pediatric ulcerative colitis |
X |
X |
X |
Rheumatoid arthritis |
X |
X |
X |
Ankylosing spondylitis |
X |
X |
X |
Psoriatic arthritis |
X |
X |
X |
Plaque psoriasis |
X |
X |
X |
Crohn Disease
Used to reduce signs and symptoms and to induce and maintain clinical remission in adults with moderately to severely active Crohn disease who have had an inadequate response to conventional therapies; also used to reduce the number of draining enterocutaneous and rectovaginal fistulas and to maintain fistula closure in adults with fistulizing Crohn disease.1 5 38 64 136 140 141 167 194 195 Designated an orphan drug by FDA for these uses.191
Sub-Q formulation of infliximab-dyyb is used for the maintenance treatment of moderately to severely active Crohn disease in adults following IV treatment with an infliximab product.225
Drugs used to treat Crohn disease in adults include 5-aminosalicylates, antibiotics, corticosteroids, immunomodulators, and biologic agents including TNF blocking agents.2000 Guidelines generally support use of infliximab for induction and maintenance therapy in adults with moderate to severe Crohn disease or fistulizing Crohn disease.2000 2001
Also used to reduce signs and symptoms and to induce and maintain clinical remission in pediatric patients ≥6 years of age with moderately to severely active Crohn disease who have had an inadequate response to conventional therapy.1 167 194 195 86 87 167 194 195 201 202 Designated an orphan drug by FDA for these uses.191
Role of TNF blocking agents in pediatric Crohn disease is generally induction and maintenance therapy in patients who fail an adequate trial of steroids and exclusive enteral nutrition and/or immunomodulators, unless there is a complex perianal fistula at diagnosis.2016
Ulcerative Colitis
Used to manage signs and symptoms, induce and maintain clinical remission and mucosal healing, and eliminate corticosteroid use in adults with moderate to severe active ulcerative colitis who have had an inadequate response to conventional therapies.1 147 167 194 195
Sub-Q formulation of infliximab-dyyb is used for the maintenance treatment of moderately to severely active ulcerative colitis in adults following IV treatment with an infliximab product.225
Drugs used to treat ulcerative colitis in adults include oral and rectal 5-aminosalicylates, oral and rectal corticosteroids, immunomodulators (e.g., thiopurines, methotrexate), tofacitinib, and biologic agents, including TNF blocking agents, vedolizumab, and ustekinumab.2018 2019 Guidelines generally support first-line use of TNF blocking agents for induction and maintenance of remission in patients with moderate to severe ulcerative colitis.2019 2020 Specific treatments for ulcerative colitis are selected according to disease severity, disease location/extent, disease prognosis, and previous therapies.2018 2019 2020
Used to manage signs and symptoms and to induce and maintain clinical remission in pediatric patients ≥6 years of age with moderate to severe active ulcerative colitis who have had an inadequate response to conventional therapies.1 167 194 195 203 Designated an orphan drug by FDA for treatment of ulcerative colitis in pediatric patients.191
Role of TNF blocking agents in pediatric ulcerative colitis is generally in patients with moderate to severe disease who fail therapy with 5-aminosalicylates/azathioprine and/or who are unable to wean from corticosteroids on 5-aminosalicylate/azathioprine therapy.2015 2016
Rheumatoid Arthritis
Used in conjunction with methotrexate to manage signs and symptoms, improve physical function, and inhibit progression of structural damage in adults with moderate to severe active rheumatoid arthritis.1 14 15 17 18 41 145 167 194 195
Disease-modifying treatments for rheumatoid arthritis include conventional disease-modifying antirheumatic drugs (DMARDs) (e.g., hydroxychloroquine, leflunomide, methotrexate, sulfasalazine), biologic DMARDs (e.g., TNF blocking agents, abatacept, tocilizumab, sarilumab, rituximab), and/or targeted synthetic DMARDs (e.g., Janus kinase inhibitors).2003
Guidelines generally support the use of TNF blocking agents as add-on therapy to methotrexate in patients who do not meet treatment goals with methotrexate alone.2003
Specific agents for rheumatoid arthritis treatment are selected according to current disease activity, prior therapies used, and the presence of comorbidities.2003
Ankylosing Spondylitis
Used to manage signs and symptoms of active ankylosing spondylitis in adults.1 137 167 194 195 ,204 205 206 207
Treatments for ankylosing spondylitis include nonsteroidal anti-inflammatory agents (NSAIAs), conventional DMARDs (e.g., methotrexate, sulfasalazine), biologic DMARDs (e.g., TNF blocking agents, secukinumab, ixekizumab), and/or targeted synthetic DMARDs (e.g., tofacitinib).2004
Guidelines generally support use of TNF blocking agents for the treatment of ankylosing spondylitis in patients with active disease despite treatment with NSAIAs.2004
Recommendations for treatment selection in ankylosing spondylitis vary based on the presence of certain comorbidities (e.g., iritis, inflammatory bowel disease).2004
Psoriatic Arthritis
Used to manage signs and symptoms, inhibit progression of structural damage, and improve physical function in adults with psoriatic arthritis.1 167 194 195 208 209 210 211 212 213 214
Disease-modifying treatments for adults with psoriatic arthritis include oral small molecules (e.g., methotrexate, sulfasalazine, cyclosporine, leflunomide, apremilast), biologic DMARDs (e.g., TNF blocking agents, secukinumab, ixekizumab, ustekinumab, brodalumab, abatacept), and/or targeted synthetic DMARDs (e.g., tofacitinib).2005
Guidelines generally support use of TNF blocking agents as first-line treatment in patients with active psoriatic arthritis.2005
Recommendations for the use and selection of disease-modifying therapies in psoriatic arthritis vary based on the presence of certain disease characteristics (e.g., psoriatic spondylitis/axial disease, enthesitis) and comorbidities (e.g., inflammatory bowel disease, diabetes).2005
Plaque Psoriasis
Used to manage chronic, severe (i.e., extensive and/or disabling) plaque psoriasis in adults who are candidates for systemic therapy and in whom other systemic therapies are medically less appropriate.1 167 194 195 215 216 217 218 219 220 Use only in patients who will be closely monitored and have regular follow-up visits with a clinician.1 167 194 195
Biologics used in the treatment of psoriasis include TNF blocking agents, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, tildrakizumab, and risankizumab.2007 2012
Guidelines generally support use of TNF blocking agents in moderate to severe psoriasis, either as monotherapy or in combination with topical, oral, or phototherapy.2007
Recommendations for the use and selection of psoriasis therapies vary based on patient age, disease characteristics (e.g., severity, location, presence of psoriatic arthritis), and comorbidities (e.g., inflammatory bowel disease).2007 2008 2009 2010 2011 2012
Juvenile Arthritis
Has been used in a limited number of pediatric patients with juvenile arthritis† [off-label]; further study needed.1 72 103 104 153
Behcet’s Syndrome
Has been used in a limited number of patients with Behcet’s syndrome† [off-label].93 102 115 116
Pyoderma Gangrenosum
Has been used in a limited number of patients with pyoderma gangrenosum† [off-label].221
Infliximab Dosage and Administration
General
Pretreatment Screening
-
Evaluate all patients for active and inactive tuberculosis prior to initiating therapy.1 167 194 195 225
-
Screen patients for hepatitis B virus (HBV) infection before initiation of therapy.1 167 194 195 225
-
Do not initiate therapy in patients with an active infection, including clinically important localized infections.1 167 194 195 225
Patient Monitoring
-
Monitor patients for infusion reactions during and for at least 30 minutes after IV infusion.1 167 194 195 72 142 Ensure that appropriate personnel and medications are available to treat infusion reactions.1 167 194 195 For patients without a history of acute infusion reactions with prior doses of the drug, monitor vital signs every 30 minutes; for patients with a history of such reactions, monitor every 15 minutes.72
-
Monitor closely for signs or symptoms of infection (e.g., fever, malaise, weight loss, sweats, cough, dyspnea, pulmonary infiltrates, serious systemic illness including shock), including the possible development of tuberculosis in patients who tested negative for latent tuberculosis prior to initiating therapy, during and after treatment with TNF blocking agents.1 155 159 167 194 195 225
-
Evaluate and monitor chronic carriers of HBV prior to the initiation of infliximab therapy, during treatment, and for several months following treatment.1 167 194 195 225
-
Perform periodic dermatologic evaluations in all patients, particularly those with risk factors for skin cancer.1 167 194 195 225
-
Monitor patients with psoriasis, particularly those who received prior prolonged phototherapy for their disease, for nonmelanoma skin cancer.1 167 194 195
-
Perform periodic screening for cervical cancer in women.1 167 194 195 225
-
Closely monitor patients during therapy for new or worsening symptoms of heart failure.1 167 194 195 225
-
Monitor hepatic enzymes and liver function tests every 3 to 4 months during subcutaneous maintenance therapy with infliximab-dyyb (Zymfentra).225
Premedication and Prophylaxis
-
May premedicate patients with histamine-1 receptor antagonists, histamine-2 receptor antagonists, acetaminophen, and/or corticosteroids to prevent infusion reactions.1 167 194 195
Dispensing and Administration Precautions
-
To avoid medication errors, the Institute for Safe Medication Practices (ISMP) recommends that prescribers communicate both the brand and generic names for infliximab products on the prescription order form.222
Other General Considerations
-
May continue treatment with agents used for management of Crohn disease or ulcerative colitis (e.g., corticosteroids, mesalamine, sulfasalazine, azathioprine, mercaptopurine, methotrexate, anti-infective agents) in patients receiving infliximab products.1 5 38 167 However, consider increased risks of hepatosplenic T-cell lymphoma with combination therapy and the observed (in infliximab studies) increase in immunogenicity and hypersensitivity reactions associated with infliximab products given as monotherapy.1 167 194 195
-
Infliximab products are used in conjunction with methotrexate for management of rheumatoid arthritis.1 167 194 195 Other nonbiologic agents used for management of rheumatoid arthritis (e.g., corticosteroids, nonsteroidal anti-inflammatory agents [NSAIAs]) may be continued in patients receiving infliximab products.1 167 194 195
-
Infliximab products can be used with or without methotrexate for management of psoriatic arthritis.1 167 194 195
Administration
IV Administration
May administer by IV infusion.1 167 194 195
Administer with an in-line, sterile, nonpyrogenic, low-protein-binding filter with a pore diameter of ≤1.2 µm.1 167 194 195
Do not admix infliximab products with other drugs of infuse in the same IV line with other drugs.1 167 194 195
Reconstitution
Reconstitute vial containing 100 mg of lyophilized infliximab product with 10 mL of sterile water for injection to provide a solution containing 10 mg/mL.1 167 Reconstitute the number of vials needed to provide the indicated dosage of infliximab product.1 167 194 195
Direct diluent toward the side of the vial with a sterile syringe and a 21-gauge or smaller needle; swirl vial gently to ensure dissolution; do not shake or agitate vigorously (to minimize foaming).1 167 194 195
Allow reconstituted solution to stand for 5 minutes before dilution.1 167 194 195
Dilution
Remove the volume of diluent equal to the total required volume of reconstituted infliximab product solution from a 250-mL bag or bottle of 0.9% sodium chloride injection.1 167 194 195 Slowly add reconstituted infliximab product to the bag or bottle to yield a total volume of 250 mL; mix gently.1 167 194 195 Final concentration of the reconstitued and diluted solution for infusion should be 0.4–4 mg/mL.1 167 194 195 For volumes >250 mL, use a larger infusion bag (e.g., 500 mL) or multiple 250 mL infusion bags to ensure that the concentration of the infusion solution does not exceed 4 mg/mL.1 167 194 195 Begin infliximab product infusion within 3 hours of reconstitution and dilution.1 167 194 195
Rate of Administration
Infuse infliximab products over a period of at least 2 hours.1 167 194 195
Manufacturer of infliximab states that IV infusions may be given at a rate of 2 mL/minute or, alternatively, a rate titration schedule may be used in an attempt to prevent or ameliorate acute infusion reactions (see Table 1).72 A rate titration schedule can be used in patients receiving an initial infliximab dose and those with or without a history of acute infusion reactions.72
Rate |
Time |
---|---|
10 mL/hour |
first 15 minutes72 |
20 mL/hour |
next 15 minutes72 |
40 mL/hour |
next 15 minutes72 |
80 mL/hour |
next 15 minutes72 |
150 mL/hour |
next 30 minutes72 |
250 mL/hour |
next 30 minutes72 |
Subcutaneous Administration
Infliximab-dyyb (Zymfentra) is approved for sub-Q administration and is intended for use under the supervision of a healthcare provider.225 After proper training, a patient or a caregiver may be able to administer sub-Q.225
Inject into front of the thighs, the abdomen (except for the 2 inches around the navel), or outer area of the upper arms (caregiver only).225 Rotate injection site each time an injection is administered with at least 1.2 inches between new and prior injection sites.225 Do not inject into red, bruised, tender, or indurated skin areas.225 If a sub-Q dose is missed, inject next dose as soon as possible and then every 2 weeks thereafter.225
Dosage
Pediatric Patients
Crohn Disease
Moderate or Severe Active Crohn Disease
IVChildren ≥6 years of age: 5 mg/kg at 0, 2, and 6 weeks (induction regimen), then every 8 weeks (maintenance regimen).1 167 194 195
Ulcerative Colitis
Moderate to Severe Active Ulcerative Colitis
IVChildren ≥6 years of age: 5 mg/kg at 0, 2, and 6 weeks (induction regimen), then every 8 weeks (maintenance regimen).1 167 194 195
Adults
Crohn’s Disease
Moderate or Severe Active Crohn Disease or Fistulizing Crohn Disease
IV5 mg/kg at 0, 2, and 6 weeks (induction regimen), then every 8 weeks (maintenance regimen).1 167 194 195
Consider dose of 10 mg/kg for patients who respond initially but subsequently lose response.1 167 194 195
Patients who do not respond by week 14 are unlikely to respond with continued administration; consider discontinuing the drug.1 167 194 195
Sub-Q (Zymfentra)Maintenance therapy following treatment with an IV induction regimen with an infliximab product: 120 mg once every 2 weeks, initiated at week 10.225
To switch patients who are responding to maintenance therapy with an infliximab product given IV, administer initial sub-Q dose in place of next scheduled IV infusion and every 2 weeks thereafter.225
Ulcerative Colitis
Moderate to Severe Active Ulcerative Colitis
IV5 mg/kg at 0, 2, and 6 weeks (induction regimen), then every 8 weeks (maintenance regimen).1 167 194 195
Sub-Q (Zymfentra)Maintenance therapy following treatment with an IV induction regimen with an infliximab product: 120 mg once every 2 weeks, initiated at week 10.225
To switch patients who are responding to maintenance therapy with an infliximab product given IV, administer initial sub-Q dose in place of next scheduled IV infusion and every 2 weeks thereafter.225
Rheumatoid Arthritis
Moderate to Severe Active Rheumatoid Arthritis
IV3 mg/kg at 0, 2, and 6 weeks (induction regimen), then every 8 weeks (maintenance regimen).1 167 194 195
Increase dosage up to 10 mg/kg every 8 weeks and/or administer as often as once every 4 weeks for patients who have an incomplete response to 3 mg/kg; consider that risk of serious infection is increased with higher dosages.1 72 167 194 195
Ankylosing Spondylitis
IV
5 mg/kg at 0, 2, and 6 weeks (induction regimen), then every 6 weeks (maintenance regimen).1 167 194 195
Psoriatic Arthritis
IV
5 mg/kg at 0, 2, and 6 weeks (induction regimen), then every 8 weeks (maintenance regimen).1 167 194 195
Plaque Psoriasis
IV
5 mg/kg at 0, 2, and 6 weeks (induction regimen), then every 8 weeks (maintenance regimen).1 167 194 195
If treatment is resumed after maintenance therapy is interrupted, reinitiate with a single dose followed by maintenance therapy.1 167 194 195
Special Populations
Hepatic Impairment
No specific dosage recommendations.1 167 194 195 225
Renal Impairment
No specific dosage recommendations.1 167 194 195 225
Geriatric Patients
No specific dosage recommendations.1 167 194 195 225
Cautions for Infliximab
Contraindications
-
Prior severe hypersensitivity reaction to infliximab products; known hypersensitivity to murine proteins or any ingredient in the formulations.1 167 194 195 225
-
Doses >5 mg/kg in patients with moderate or severe heart failure.1 167 194 195
Warnings/Precautions
Warnings
Serious Infections
Increased risk of serious infections; may result in hospitalization or death.1 159 167 194 195 225 (See Boxed Warning.)
Opportunistic infections caused by bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms (e.g., aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, cryptococcosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, salmonellosis, tuberculosis) reported, particularly in patients receiving concomitant therapy with immunosuppressive agents (e.g., methotrexate, corticosteroids).1 72 118 155 159 Infections frequently are disseminated.1
Increased incidence of serious infections observed with concomitant use of a TNF blocking agent and anakinra or abatacept.1 Concomitant use of infliximab and anakinra, abatacept, or other biological products used to treat the same conditions as infliximab not recommended.1 167 194 195
Risk of infection is increased in patients >65 years of age and those with comorbid conditions and/or receiving concomitant therapy with immunosuppressive agents (e.g., corticosteroids, methotrexate).1 159 167 194 195 225
Do not initiate infliximab in patients with active infections, including clinically important localized infections.1 167 194 195 225 Consider potential risks and benefits prior to initiating therapy in patients with a history of chronic, recurring, or opportunistic infections; patients with underlying conditions that may predispose them to infections; and patients who have been exposed to tuberculosis or who have resided or traveled in regions where tuberculosis or mycoses such as histoplasmosis, coccidioidomycosis, and blastomycosis are endemic.1 159 167 194 195 225
Closely monitor patients during and after infliximab therapy for signs or symptoms of infection (e.g., fever, malaise, weight loss, sweats, cough, dyspnea, pulmonary infiltrates, serious systemic illness including shock).1 155 159 167 194 195 225
If new infection occurs during infliximab product therapy, perform thorough diagnostic evaluation (appropriate for immunocompromised patient), initiate appropriate anti-infective therapy, and closely monitor patient.1 155 167 194 195 225 Discontinue therapy if serious infection or sepsis develops.1 34 35 44 118 155 167 194 195 225
Evaluate all patients for active or latent tuberculosis and for risk factors for tuberculosis prior to and periodically during therapy with infliximab.1 72 118 159 167 194 195 225 When indicated, initiate appropriate antimycobacterial regimen for treatment of latent tuberculosis infection prior to infliximab therapy.1 72 118 167 194 195 225 Also consider antimycobacterial therapy prior to use of infliximab in individuals with a history of latent or active tuberculosis in whom an adequate course of antimycobacterial treatment cannot be confirmed and for individuals with a negative tuberculin skin test who have risk factors for tuberculosis.1 167 194 195 225 Consultation with a tuberculosis specialist is recommended when deciding whether to initiate antimycobacterial therapy.1 167 194 195 225
Monitor all patients, including those with negative tuberculin skin tests, for active tuberculosis.1 167 194 195 225 Strongly consider tuberculosis in patients who develop new infections while receiving infliximab, especially if they previously have traveled to countries where tuberculosis is highly prevalent or have been in close contact with an individual with active tuberculosis.1 167 194 195 225 Active tuberculosis reported in some patients receiving infliximab while receiving therapy for latent tuberculosis.1 167 194 195
Failure to recognize invasive fungal infections has led to delays in appropriate treatment.155 Serologic tests for histoplasmosis may be negative in some patients with active infection.1 167 194 195 225 Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.1 155 159 167 194 195 225 Whenever feasible, consult specialist in fungal infections when making decisions regarding initiation and duration of antifungal therapy.1 155 167 194 195 225
When deciding whether to reinitiate TNF blocking agent therapy following resolution of an invasive fungal infection, reevaluate risks and benefits, particularly in patients who reside in regions where mycoses are endemic.155 Whenever feasible, consult specialist in fungal infections.155
Malignancies
Lymphoma and other malignancies (some fatal) reported during postmarketing surveillance in children and adolescents receiving TNF blocking agents, particularly in those receiving other immunosuppressive agents (e.g., azathioprine, methotrexate) concomitantly.1 154 167 194 195 225 (See Boxed Warning.)
Malignancies included lymphomas (e.g., Hodgkin disease, non-Hodgkin lymphoma) and various other malignancies (e.g., leukemia, melanoma, solid organ cancers), including rare malignancies usually associated with immunosuppression and malignancies not usually observed in children and adolescents (e.g., leiomyosarcoma, hepatic malignancies, renal cell carcinoma).1 154 167 Median time to occurrence was 30 months (range: 1–84 months) after initial dose.1 167 FDA has concluded that there is an increased risk of malignancy with TNF blocking agents in children and adolescents; however, strength of association not fully characterized.154
Hepatosplenic T-cell lymphoma (a rare, aggressive, usually fatal T-cell lymphoma) reported mainly in adolescent and young adult males with Crohn disease or ulcerative colitis receiving TNF blocking agents and/or thiopurine analogs (mercaptopurine or azathioprine).1 154 160 167 194 195 225 Most patients received a combination of immunosuppressive agents, including TNF blocking agents and thiopurine analogs.1 160 167 194 195 225 Unclear whether occurrence is related to TNF blocking agents or combination of TNF blocking agents and other immunosuppressive agents.1 167 194 195
Patients with Crohn disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or plaque psoriasis, especially those with highly active disease and/or chronic exposure to immunosuppressive therapies, may be at increased risk of lymphoma;1 28 30 38 42 160 167 194 195 225 added risk from TNF blocking agents may be difficult to assess.160
Acute and chronic leukemias (some fatal) reported during postmarketing surveillance of TNF blocking agents in adults and pediatric patients, particularly in those receiving other immunosuppressive agents concomitantly.1 154 167 194 195 225 Leukemia (most commonly acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia) generally occurred during first 2 years of therapy.154 FDA has concluded that there is a possible association between TNF blocking agents and development of leukemia; however, interpretation of findings is complicated because patients with rheumatoid arthritis may be at increased risk for leukemia independent of any treatment with TNF blocking agents.1 154 167
Malignancies (mainly lung cancer or head and neck malignancies) reported in more infliximab-treated than placebo-treated patients with moderate to severe COPD† [off-label]; all patients were heavy smokers.1 157 Exercise caution when considering infliximab therapy in patients with moderate to severe COPD.1 167 194 195
In infliximab-treated psoriasis patients, nonmelanoma skin cancer reported more commonly in those who received prior phototherapy; monitor psoriasis patients receiving infliximab, especially those who have received prolonged prior phototherapy, for nonmelanoma skin cancer.1 167 194 195
Melanoma and Merkel cell carcinoma also reported.1 167 194 195 225 Periodic skin examination recommended for all patients, particularly those with risk factors for skin cancer.1 167 194 195 225
Incidence of invasive cervical cancer in women with rheumatoid arthritis treated with infliximab appears to be higher than biologic-naïve patients or the general population, particularly those >60 years of age.1 167 194 195 Periodic screening for cervical cancer recommended for women treated with infliximab.1 167 194 195 225
Other malignancies (basal cell carcinoma, breast cancer, colorectal cancer, rectal adenocarcinoma, squamous cell carcinoma) also reported.1 14 17 141
Consider possibility of and monitor for occurrence of malignancies during and following treatment with TNF blocking agents.154 160
Exercise caution when considering infliximab therapy in patients with a history of malignancy or when deciding whether to continue therapy in patients who develop a malignancy.1 33 34 35 44 59 64 167 194 195 Carefully consider risks and benefits of TNF blocking agents, especially in adolescent and young adult males and in those with Crohn disease or ulcerative colitis.1 160 167 194 195 225
When deciding whether to use infliximab alone or in combination with other immunosuppressive agents, consider both the possibility of an increased risk of hepatosplenic T-cell lymphoma with combination therapy and the observed increase in immunogenicity and hypersensitivity reactions associated with infliximab given as monotherapy.1 167 194 195 225
Hypersensitivity Reactions
Hypersensitivity reactions reported; these reactions vary in time to onset and require hospitalization in some patients.1 167 194 195 225 Most hypersensitivity reactions occurred during or within 2 hours of infusion; reactions have included anaphylaxis, urticaria, dyspnea, and hypotension.1 36 128 167 194 195
Patients with antibodies to the drug were 2–3 times more likely to have an infusion reaction than patients who did not have antibodies to the drug.1
Incidence of acute infusion reactions in infliximab-treated patients may be lower in those receiving concomitant therapy with immunosuppressive agents (e.g., azathioprine, mercaptopurine, methotrexate).1 47 167
Drugs for treatment of hypersensitivity reactions (e.g., acetaminophen, antihistamines, corticosteroids, and/or epinephrine) should be immediately available.1 72 167 194 195
Monitor patients and consider premedication; initiate infusion slowly and adjust rate or discontinue based on patient tolerance.1 5 10 14 18 23 28 38 42 47 72 92 167 194 195
Discontinue infliximab immediately if a severe hypersensitivity reaction occurs; initiate appropriate therapy.1 167 194 195
Readministration of infliximab after a period without treatment associated with a higher incidence of infusion reactions compared with regular maintenance treatment.1 Carefully consider risks and benefits of infliximab readministration after a period without treatment (especially readministration as a reinduction regimen at 0, 2, and 6 weeks); in patients with psoriasis, reinitiate infliximab treatment with a single dose followed by maintenance therapy.1 167 194 195
Other Warnings and Precautions
HBV Reactivation
Reactivation of HBV infection may occur in patients who are chronic carriers of the virus (i.e., hepatitis B surface antigen-positive [HBsAg-positive]).1 167 194 195 225 Use of multiple immunosuppressive agents may contribute to HBV reactivation.1 167 194 195 225
Screen all patients prior to initiation of infliximab therapy.1 167 194 195 225 Consultation with expert in treatment of hepatitis B is recommended for HBsAg-positive patients.1 167 194 195 225 Evaluate and monitor HBV carriers before, during, and for up to several months after therapy.1 167 194 195 225
Safety and efficacy of antiviral therapy for prevention of HBV reactivation not established.1 167 194 195 225
Discontinue infliximab and initiate appropriate treatment (e.g., antiviral therapy) if HBV reactivation occurs.1 167 194 195 225
Not known whether infliximab can be readministered once control of a reactivated HBV infection is achieved; caution advised in this situation.1 167 194 195 225
Hepatotoxicity
Severe hepatic reactions (e.g., acute liver failure, jaundice, hepatitis, cholestasis) reported; some cases were fatal or needed liver transplantation.1 167 194 195 225 Hepatic reactions occurred between 2 weeks and >1 year following initiation of therapy; elevations of hepatic transaminase enzymes not observed prior to discovery of liver injury in many cases.1
Evaluate patients with signs of liver dysfunction.1 167 194 195 If jaundice and/or marked hepatic aminotransferase elevations (≥5 times the ULN) develop, discontinue drug and investigate hepatic abnormality.1 167 194 195
Monitor hepatic enzymes and liver function tests every 3 to 4 months during sub-Q maintenance treatment with infliximab-dyyb (Zymfentra).225 Interrupt this treatment if drug-induced liver injury is suspected, until the diagnosis is excluded.225
Heart Failure
Infliximab may cause adverse outcomes in patients with heart failure (increased mortality and hospitalization due to worsening heart failure).1 139 167 194 195
Use of infliximab in patients with heart failure (NYHA class III or IV) associated with increased mortality in patients who received infliximab 10 mg/kg and increased adverse cardiovascular effects (dyspnea, hypotension, angina, dizziness) in patients who received 5 or 10 mg/kg.1 Worsening heart failure (with and without identifiable precipitating factors) and new-onset heart failure (including in patients with no known preexisting cardiovascular disease and/or who were <50 years of age) reported.1 Not evaluated in patients with mild (NYHA class I or II) heart failure.1
Use infliximab in patients with heart failure with caution and careful monitoring.1 167 194 195 225 If used in patients with moderate or severe heart failure, do not exceed doses of 5 mg/kg and monitor cardiac status closely.1 167 194 195
Discontinue therapy if new or worsening symptoms of heart failure occur.1 167 194 195 225
Hematologic Reactions
Possible leukopenia, neutropenia, thrombocytopenia, and pancytopenia, sometimes with fatal outcome.1 167 194 195 225 Use infliximab with caution in patients with a history of substantial hematologic abnormalities.1 167 194 195 225 Consider discontinuance of the drug in patients with confirmed hematologic abnormalities.1 167 194 195 225
Cardiovascular and Cerebrovascular Reactions
Serious cerebrovascular accidents, myocardial ischemia/infarction (sometimes fatal), hypotension, hypertension, and arrhythmias reported during and within 24 hours of infliximab infusion.1 167 194 195 Cases of transient visual loss also reported during and within 2 hours of infliximab product infusion1 167 194 195
Monitor patients for these events during infusion; if a serious reaction occurs, discontinue infusion and manage reaction as dictated by signs and symptoms.1 167 194 195
Neurologic Reactions
CNS manifestations of systemic vasculitis, seizures, and new onset or exacerbation of central or peripheral nervous system demyelinating disorders (e.g., multiple sclerosis, optic neuritis, Guillain-Barré syndrome) reported rarely in patients receiving infliximab or other TNF blocking agents.1 167 194 195 225
Exercise caution when considering infliximab in patients with these neurologic disorders.1 167 194 195 225 Consider discontinuance of the drug if these disorders develop.1 167 194 195 225
Concurrent Administration with Other Biological Products
Serious infections and neutropenia reported with concurrent use of anakinra and another TNF blocker without increased clinical benefit compared to the TNF blocker alone.1 167 194 195 225 Similar toxicities may also result from concurrent use of anakinra and other TNF blockers.1 167 194 195 Concurrent use of infliximab and anakinra not recommended.1 167 194 195
Concurrent administration of TNF blockers and abatacept associated with increased risk of infections including serious infections compared with TNF blockers alone, without increased clinical benefit.1 167 194 195 Concurrent use of infliximab and abatacept not recommended.1
Insufficient information regarding concurrent use of infliximab with other biological products used to treat the same conditions as infliximab.1 167 194 195 Concurrent use of infliximab with these biological products not recommended because of possibility of increased risk of infection.1 167 194 195
Switching Between Biological Disease-Modifying Antirheumatic Drugs (DMARDs)
Care should be taken when switching from one biologic to another, since overlapping biological activity may further increase risk of infection.1 167 194 195
Immunologic Reactions and Antibody Formation
Possible formation of autoimmune antibodies.1 167 194 195 Lupus-like syndrome reported.1 If manifestations suggestive of lupus-like syndrome develop, discontinue infliximab product therapy.1 167 194 195
Infliximab therapy may result in the formation of antibodies to infliximab.1 167 194 195 225 Antibody-positive patients more likely to experience an infusion reaction.1 10 23 85
No clinically meaningful differences between infliximab biosimilars and infliximab with respect to antidrug antibody response.168 223 224
Immunization
Avoid live vaccines.1 167 194 195 225
When considering infliximab therapy, review vaccination status of patient and administer all age-appropriate vaccines included in current immunization guidelines prior to initiating therapy.1 167 194 195 225
Do not administer live vaccines to infants exposed to infliximab in utero for at least 6 months after birth.1 167 194 195 225
Use of therapeutic infectious agents (e.g., BCG bladder instillation for the treatment of cancer) not recommended with concurrent administration of infliximab.1 167 194 195 225
Specific Populations
Pregnancy
No increased risk of major malformations among live births shown in available observational studies.1 167 194 195 225 However, findings on other birth and maternal outcomes not consistent across studies.1 167 194 195
Crosses placenta during third trimester of pregnancy and may affect immune responses in infants exposed in utero.1 167 194 195 225 Infliximab has been detected for up to 6 months in serum of infants whose mothers received infliximab products during pregnancy.1 167 194 195 225
Animal reproduction studies not conducted.1 In a developmental toxicity study in mice using an analogous antibody, no evidence of maternal toxicity, fetal mortality, or structural abnormalities observed.1
Lactation
Clinical studies indicate IV infliximab is present in human milk at low levels.1 167 194 195 225 Systemic exposure in a breastfed infant expected to be low.1 167 194 195 225 No data on effects of infliximab on milk production.1 167 194 195 225 Consider developmental and health benefits of breastfeeding, along with the mother’s clinical need for the infliximab product and potential adverse effects on the breastfed infant from the drug or underlying maternal condition.1 167 194 195 225
Pediatric Use
Safety and efficacy of IV infliximab established in children ≥6 years of age with Crohn disease; infliximab studied in this age group only in conjunction with conventional immunosuppressive agents.1 167 194 195 Safety and efficacy of long-term (>1 year) therapy not established.1 167 194 195
Safety and efficacy of IV infliximab established in pediatric patients ≥6 years of age with ulcerative colitis.1 167 194 195 Safety and efficacy of long-term (>1 year) therapy not established.1
Safety and efficacy of infliximab products in pediatric patients with plaque psoriasis not established.1 167 167
Infliximab has been studied in children 4–17 years of age with juvenile arthritis† [off-label] who had not responded adequately to methotrexate.1 153 Further study needed to evaluate safety and efficacy.1 72 104 153
Malignancies, some fatal, reported in children and adolescents who received TNF blocking agents.1 154 160 167 194 167
Carefully assess risks and benefits when deciding whether to use infliximab products alone or in combination with other immunosuppressive agents.1 167 194 195 Use of infliximab products in the absence of other immunosuppressive agents may increase the likelihood of infliximab-specific antibody formation and increase the risk of hypersensitivity reactions.1 167 Unclear whether reported cases of hepatosplenic T-cell lymphoma related to TNF blocking agents or use of TNF blocking agents in conjunction with other immunosuppressive agents.1 167 194 195
Ensure that all vaccinations are up to date prior to initiating infliximab therapy in pediatric patients.1 167 194 195 194 195
Infliximab detected for up to 6 months in the serum of infants whose mothers received infliximab products during pregnancy.1 167 194 195 Infants exposed to infliximab in utero may be at increased risk of infection; fatal disseminated BCG infection reported in an infant who received BCG vaccine after having been exposed to infliximab in utero.1 167 194 195 Infants exposed to infliximab in utero should not receive live vaccines (e.g., BCG vaccine, rotavirus vaccine live oral) for ≥6 months after birth.1 167 194 195
Safety and efficacy of infliximab-dyyb (Zymfentra) not established in pediatric patients.225
Geriatric Use
Rheumatoid arthritis, plaque psoriasis: No substantial difference in safety or efficacy relative to younger adults in clinical studies of infliximab.1 167 194 195
Crohn disease, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis: Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.1 167 194 195
Possible increased incidence of infections in geriatric patients; use infliximab products with caution.1 167 194 195
Hepatic Impairment
Infliximab products not studied in patients with hepatic impairment.1 167 194 195 225
Renal Impairment
Infliximab products not studied in patients with renal impairment.1 167 194 195 225
Common Adverse Effects
Common adverse effects (≥10%) in patients receiving IV infliximab products: infections (e.g., upper respiratory, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain.1 167 194 195
Adverse effects (≥3%) in patients receiving subcutaneous infliximab-dyyb for ulcerative colitis include COVID-19, anemia, arthralgia, injection site reaction, increased alanine aminotransferase, abdominal pain.225
Adverse effects (≥3%) in patients receiving subcutaneous infliximab-dyyb for Crohn disease include COVID-19, headache, upper respiratory tract infection, injection site reaction, diarrhea, increased blood creatine phosphokinase, arthralgia, increased alanine aminotransferase, hypertension, urinary tract infection, neutropenia, dizziness, leukopenia.225
Drug Interactions
No formal drug interaction studies to date.1 167 194 195 225
Administered concomitantly with corticosteroids, mesalamine or sulfasalazine, azathioprine or mercaptopurine, and/or anti-infective agents in patients with Crohn disease; serum concentrations of infliximab not affected by corticosteroids, mesalamine or sulfasalazine, or anti-infectives (ciprofloxacin, metronidazole).1 5 6 38 64 69 167
Administered concomitantly with methotrexate, corticosteroids, NSAIAs, folic acid, and narcotics in patients with rheumatoid arthritis or psoriatic arthritis.1 14 15 17 18 41 167
Administered concomitantly with corticosteroids, azathioprine or mercaptopurine, and/or 5-aminosalicylates in patients with ulcerative colitis.1 147 167
Drugs Metabolized by Hepatic Microsomal Enzymes
Because increased levels of cytokines (e.g., TNF-α) during chronic inflammation may suppress formation of CYP isoenzymes, antagonism of cytokine activity by infliximab products may normalize formation of CYP enzymes.1 167 194 195 225
Drugs metabolized by CYP isoenzymes that have a low therapeutic index: Monitor therapeutic effect and serum concentrations following initiation or discontinuance of infliximab products; adjust dosage as needed.1 167 194 195 225
Biologic Agents
Use caution when switching from one biologic DMARD to another, since overlapping biologic activity may further increase the risk of infection.1 167 194 195
Insufficient data regarding concomitant use of infliximab products with other biologic agents used to treat the same conditions.1 167 194 195 Concomitant use not recommended because of an increased risk of infection.1 167 194 195 225
Immunosuppressive Agents
Incidence of some adverse immunologic reactions (e.g., infusion reactions, formation of antibodies to infliximab) decreased in patients receiving infliximab and immunosuppressive agents concomitantly.1 18
When deciding whether to use infliximab products alone or in combination with other immunosuppressive agents, consider both the possibility of an increased risk of hepatosplenic T-cell lymphoma with combination therapy and the observed (in infliximab studies) increase in immunogenicity and hypersensitivity reactions associated with infliximab products given as monotherapy.1 167 194 195
Vaccines and Therapeutic Infectious Agents
Live vaccines: Avoid concomitant use.1 167 194 195 225 Risk of infections, including disseminated infections.1 167 194 195 Limited data regarding response to live vaccines or secondary transmission of infection by live vaccines.1 167 194 195 Infants exposed to infliximab products in utero should not receive live vaccines for ≥6 months after birth.1 167 194 195 225
Live therapeutic infectious agents: Avoid concomitant use.1 167 194 195 225 Risk of infections, including disseminated infections.1 167 194 195 225
Specific Drugs
Drug |
Interaction |
Comments |
---|---|---|
Abatacept |
Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis;1 similar toxicities expected with infliximab products and abatacept1 167 194 195 |
Concomitant use not recommended1 167 194 195 Use caution when switching from one biologic DMARD to another, since overlapping biologic activity may further increase risk of infection1 167 194 195 |
Anakinra |
Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with anakinra and etanercept (another TNF blocking agent);1 167 194 195 similar toxicities expected with infliximab products and anakinra1 167 194 195 |
Concomitant use not recommended1 167 194 195 Use caution when switching from one biologic DMARD to another, since overlapping biologic activity may further increase risk of infection1 167 194 195 |
BCG for intravesical instillation |
Risk of infections, including disseminated infections1 167 194 195 225 |
|
Cyclosporine |
Possible effect on cyclosporine metabolism; because increased levels of cytokines (e.g., TNF-α) during chronic inflammation may suppress formation of CYP isoenzymes, antagonism of cytokine activity by infliximab products may normalize formation of CYP enzymes1 167 194 195 |
Monitor therapeutic effect and serum concentrations of cyclosporine following initiation or discontinuance of infliximab products; adjust dosage as needed1 167 194 195 |
Methotrexate |
Possible decreased clearance18 39 and increased concentrations of infliximab1 Possible decrease in rate of development of antibodies to infliximab 1 |
Interaction not studied specifically;13 17 18 23 25 84 85 used concomitantly in clinical studies 13 17 18 23 25 39 84 85 |
Theophylline |
Possible effect on theophylline metabolism; because increased levels of cytokines (e.g., TNF-α) during chronic inflammation may suppress formation of CYP isoenzymes, antagonism of cytokine activity by infliximab products may normalize formation of CYP enzymes1 167 194 195 |
Monitor therapeutic effect and serum concentrations of theophylline following initiation or discontinuance of infliximab products; adjust dosage as needed1 167 194 195 |
Tocilizumab |
Possibility of increased immunosuppression and increased risk of infection1 167 194 195 |
Avoid concomitant use1 167 194 195 Use caution when switching from one biologic DMARD to another, since overlapping biologic activity may further increase risk of infection1 167 194 195 |
Warfarin |
Possible effect on warfarin metabolism; because increased levels of cytokines (e.g., TNF-α) during chronic inflammation may suppress formation of CYP isoenzymes, antagonism of cytokine activity by infliximab products may normalize formation of CYP enzymes1 167 194 195 |
Monitor therapeutic effect of warfarin following initiation or discontinuance of infliximab products; adjust dosage as needed1 167 194 195 |
Infliximab Pharmacokinetics
Pharmacokinetic similarity between infliximab and its biosimilars demonstrated; FDA considers that the pharmacokinetic data provide support for a totality-of-evidence determination for infliximab-abda, infliximab-axxq, and infliximab-dyyb.168 174 176 177 188 193 223 224
Absorption
Infliximab: Systemic accumulation does not appear to occur in adults receiving multiple IV infusions once every 4 or 8 weeks following an initial 3-dose induction regimen.1 38 39 41
Distribution
Extent
Infliximab: Distribution into body tissues and fluids, including joints, has not been fully characterized.39
Infliximab products cross the placenta.1 167 194 195 225
Infliximab present in human milk at low levels.1
Elimination
Metabolism
Infliximab: Metabolic fate not fully characterized; the drug may be eliminated by the reticuloendothelial system.1 47
Infliximab: Not metabolized by CYP isoenzymes.39
Half-life
Infliximab: 8–12 days in adults with Crohn disease, rheumatoid arthritis, or plaque psoriasis.1 14 41
Sub-Q: 332 hours (after single sub-Q dose)225
Special Populations
No differences in clearance of infliximab observed in patient subgroups defined by age, weight, or gender.1 Clearance increased in patients who developed antibodies to the drug.1
Stability
Storage
Parenteral
Powder for Injection
2–8°C.1 167 194 195 May store unopened vial of infliximab or infliximab-abda at temperatures up to 30°C for single period of up to 6 months; following removal from refrigerated storage, do not return to refrigerated storage.1 194
Prepare diluted solutions of the drug immediately prior to use.1 167 194 195
Protect vials of infliximab-axxq from light.195
Sub-Q Injection
2-8°C.225 Do not freeze.225 Keep in outer carton until administration time to protect from light.225
Actions
-
Potent antagonist of TNF biologic activity.1 7 20 24 167 194 195 225
-
Has high specificity and affinity for TNF (TNF-α); does not bind to or inactivate lymphotoxin α (TNF-β).1 7 20 24 167 194 195 225 Prevents the binding of TNF to cell surface TNF receptors, thereby blocking the biologic activity of TNF.1 7 20 24 167 194 195 225
-
A chimeric human-murine immunoglobulin G1 kappa (IgG1 kappa) monoclonal antibody.1 7 20 24 167 194 195 225
-
The exact mechanism of the anti-inflammatory effects in Crohn disease or rheumatoid arthritis remain to be more fully determined; binding and neutralization of TNF appears to be a principal mechanism.1 3 5 7 8 9 25 33 37 38 39 42 43 50 57 59
-
Produced by continuous fermentation of a mouse myeloma cell line that has been transinfected with cloned DNA coding for the chimeric antibody; purified by measures to inactivate and remove viruses.1 7 20
Advice to Patients
-
Advise patients or their caregivers about the potential benefits and risks of receiving infliximab products.1 167 194 195 225 Provide a copy of the manufacturer’s patient information (Medication Guide) for infliximab products to all patients or their caregivers prior to each infusion session.1 167 194 195
-
Risk of increased susceptibility to infection.1 167 194 195 225 Inform patients or their caregivers to seek immediate medical attention if signs and symptoms suggestive of infection (e.g., fever; fatigue; cough; warm, red, or painful skin; sores on the body) develop.1 167 194 195 225
-
Risk of malignancies, including lymphoma, with use of TNF blocking agents in children, adolescents, and young adults.1 167 194 195 225 Advise patients to promptly inform clinicians if signs and symptoms of malignancies occur (e.g., unexplained weight loss; fatigue; abdominal pain; persistent fever; night sweats; easy bruising or bleeding; swollen lymph nodes in the neck, underarm, or groin; hepatomegaly or splenomegaly).154 160
-
Inform patients or their caregivers to immediately notify their clinician if manifestations of liver dysfunction (e.g., jaundice, dark brown urine, right-sided abdominal pain, fever, fatigue) occur.1 167 194 195 225
-
Advise patients or their caregivers to seek immediate medical attention if any new or worsening symptoms of heart failure occur.1 167 194 195 225
-
Advise patients or their caregivers to inform their clinician if they develop signs and symptoms suggestive of blood dyscrasias or infection (e.g., persistent fever).1 167 194 195 225
-
Advise the patient or their caregivers to seek immediate medical care if they develop symptoms of serious hypersensitivity reactions,1 167 194 195 225
-
Advise the patient or their caregivers to seek immediate medical care if they develop symptoms of cardiovascular and cerebrovascular reactions during and within 24 hours of the infliximab infusion.1 167 194 195
-
Advise the patient or their caregivers to seek medical care if they develop signs or symptoms of neurologic reactions.1 167 194 195 225
-
Advise patients or their caregivers of the importance to avoid receiving live vaccines or therapeutic infectious agents.1 167 194 195 225 For postpartum women who received infliximab products during pregnancy, inform the infant's clinician of this use since alteration of the infant's vaccination schedule may be indicated.1 167 194 195 225
-
Advise women to inform their clinician if they are or plan to become pregnant or plan to breast-feed.1 167 194 195 225
-
Advise patients or their caregivers to inform their healthcare provider about all concomitant medications, including prescription medicine, over the counter drugs, vitamins, and herbal products.1 167 194 195 225
-
Inform patients or their caregivers of other important precautionary information.1 167 194 195 225
Additional Information
The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are advised that decisions regarding use of drugs are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and that the information contained in the monograph is provided for informational purposes only. The manufacturer’s labeling should be consulted for more detailed information. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information contained in the monograph is not a substitute for medical care.
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Parenteral |
For injection, for IV infusion |
100 mg |
Remicade |
Janssen |
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Parenteral |
For injection, for IV infusion |
100 mg |
Renflexis |
Organon |
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Parenteral |
For injection, for IV infusion |
100 mg |
Avsola |
Amgen |
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Parenteral |
For injection, for IV infusion |
100 mg |
Inflectra |
Pfizer |
For subcutaneous injection |
120 mg/mL |
Zymfentra (available as single-dose prefilled syringe, single-dose prefilled syringe with needle shield, and single-dose prefilled pen) |
AHFS DI Essentials™. © Copyright 2024, Selected Revisions May 10, 2024. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.
References
1. Janssen Biotech, Inc. Remicade (infliximab) for IV injection prescribing information. Horsham, PA; 2021 Oct.
3. Van Hogezand RA, Verspaget HW. The future role of anti-tumour necrosis factor-α products in the treatment of Crohn’s disease. Drugs. 1998; 56:299-305. http://www.ncbi.nlm.nih.gov/pubmed/9777308?dopt=AbstractPlus
4. D’Haens G, van Deventer S, van Hogezand R et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European Multicenter Trial. Gastroenterology. 1999; 116:1029-34. http://www.ncbi.nlm.nih.gov/pubmed/10220494?dopt=AbstractPlus
5. Targan SR, Hanauer SB, Van Deventer SJH. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med. 1997; 337:1029-35. http://www.ncbi.nlm.nih.gov/pubmed/9321530?dopt=AbstractPlus
6. van Dullemen HM, van Deventer SJH, Hommes DW et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129-35. http://www.ncbi.nlm.nih.gov/pubmed/7797011?dopt=AbstractPlus
7. Knight DM, Trinh H, Le Junming L et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993; 30:1443-53. http://www.ncbi.nlm.nih.gov/pubmed/8232330?dopt=AbstractPlus
8. Scallon BJ, Moore MA, Trinh H et al. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine.1995;7:251-9.
9. Siegel SA, Shealy DJ, Nakada MT et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine. 1995;7:15-25. http://www.ncbi.nlm.nih.gov/pubmed/7538333?dopt=AbstractPlus
10. Mouser JF, Hyams JS. Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn’s disease. Clin Ther. 1999;21:932-42. http://www.ncbi.nlm.nih.gov/pubmed/10440618?dopt=AbstractPlus
12. Hochberg MC, Chang RW, Dwosh I et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992; 35:498-502. http://www.ncbi.nlm.nih.gov/pubmed/1575785?dopt=AbstractPlus
13. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995; 38:727-35. http://www.ncbi.nlm.nih.gov/pubmed/7779114?dopt=AbstractPlus
14. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet. 1999; 354:1932-9. http://www.ncbi.nlm.nih.gov/pubmed/10622295?dopt=AbstractPlus
15. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000; 343:1594-1602. http://www.ncbi.nlm.nih.gov/pubmed/11096166?dopt=AbstractPlus
17. Antoni C; Kalden JR. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor α antibody (infliximab) with methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol. 1999. 17(Suppl 18):S73-7.
18. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-63. (IDIS 411263). http://www.ncbi.nlm.nih.gov/pubmed/9751087?dopt=AbstractPlus
19. Jones RE, Moreland LW. Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull Rheum Dis. 1999; 48:1-4. http://www.ncbi.nlm.nih.gov/pubmed/10408141?dopt=AbstractPlus
20. Elliot MJ, Maini RN, Feldmann M et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum. 1993; 36:1681-90. http://www.ncbi.nlm.nih.gov/pubmed/8250987?dopt=AbstractPlus
21. Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105-10. http://www.ncbi.nlm.nih.gov/pubmed/7934491?dopt=AbstractPlus
23. Elliott MJ, Maini RN, Feldmann M et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet. 1994;344:1125-7. http://www.ncbi.nlm.nih.gov/pubmed/7934495?dopt=AbstractPlus
24. Breedveld FC. Therapeutic monoclonal antibodies. Lancet. 2000; 355:735-40. http://www.ncbi.nlm.nih.gov/pubmed/10703815?dopt=AbstractPlus
25. Feldman M, Charles P, Taylor P et al. Biological insights from clinical trials with anti-TNF therapy. Sem Immunopathol. 1998; 20:211-28.
28. Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999;13(Suppl 4):16-22. http://www.ncbi.nlm.nih.gov/pubmed/10597335?dopt=AbstractPlus
30. Bickston SJ, Lichtenstein GR, Arseneau KO et al. The relationship between infliximab treatment and lymphoma in Crohn’s disease. Gastroenterology. 1999;117:1433-7. http://www.ncbi.nlm.nih.gov/pubmed/10579985?dopt=AbstractPlus
33. Kavanaugh AF. Anti-tumor necrosis factor-α monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin N Am. 1998;24:593-614.
34. Furst DE, Breedveld FC, Kalden JR et al. Building towards a consensus for the use of tumour necrosis factor blocking agents. Ann Rheum Dis. 1999; 58:725-6. http://www.ncbi.nlm.nih.gov/pubmed/10577955?dopt=AbstractPlus
35. Furst DE, Breedveld FC, Burmester GR et al. Access to disease modifying treatments for rheumatoid arthritis patients. Ann Rheum Dis. 1999; 58(Suppl 1):1129-30.
36. Soykan I, Ertan C, Ozden A. Severe anaphylactic reaction to infliximab: report of a case. Am J Gastroenterol. 2000; 95:2395-6. http://www.ncbi.nlm.nih.gov/pubmed/11007258?dopt=AbstractPlus
37. Camussi G, Lupia E. The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Drugs. 1998;55:613-20. http://www.ncbi.nlm.nih.gov/pubmed/9585859?dopt=AbstractPlus
38. Rutgeerts P, D’Haens G, Targan S et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology. 1999;117:761-9. http://www.ncbi.nlm.nih.gov/pubmed/10500056?dopt=AbstractPlus
39. Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs. 2000;59:1341-59. http://www.ncbi.nlm.nih.gov/pubmed/10882166?dopt=AbstractPlus
40. McCloskey RV. Dear doctor letter regarding new prescribing information for infliximab. Malvern, PA: Centocor Inc; 1998 Nov 10.
41. Kavanaugh A, St. Clair EW, McCune WJ et al. Chimeric anti-tumor necrosis factor-α monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol. 2000; 27:841-50. http://www.ncbi.nlm.nih.gov/pubmed/10782805?dopt=AbstractPlus
42. Feldman M, Elliott MJ, Woody JN. Anti-tumor necrosis factor-α therapy of rheumatoid arthritis. Advan Immunol. 1997; 64:283-350.
43. Miani RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Ann Rev Med. 2000;51:207-29. http://www.ncbi.nlm.nih.gov/pubmed/10774461?dopt=AbstractPlus
44. Furst DE, Keystone E, Maini RN et al. Recapitulation of the round-table discussion—assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 1999; 38(Suppl 2):50-3. http://www.ncbi.nlm.nih.gov/pubmed/10646494?dopt=AbstractPlus
47. Reviewers’ comments (personal observations).
49. Chu CQ, Field M, Feldmann M et al Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 1991; 34:1125-32.
50. Van Deveneter SJH. Review article: targeting TNFα as a key cytokine in the inflammatory processes of Crohn’s disease—the mechanisms of action of infliximab. Aliment Pharmacol Ther. 1999; 13(Suppl 4):3-8.
51. Rutgeerts PJ. Review article: efficacy of infliximab in Crohn’s disease—induction and maintenance of remission. Aliment Pharmacol Ther. 1999;13(Suppl 4):9-15. http://www.ncbi.nlm.nih.gov/pubmed/10597334?dopt=AbstractPlus
52. Tak PP, Taylor PC, Breedveld FC et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1996; 39:1077-81. http://www.ncbi.nlm.nih.gov/pubmed/8670314?dopt=AbstractPlus
53. Paleolog EM, Hunt M, Elliott MJ et al. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum. 1996; 39:1082-91. http://www.ncbi.nlm.nih.gov/pubmed/8670315?dopt=AbstractPlus
54. Paleolog EM, Young S, Stark AC et al. Modulation of anagiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. 1998; 41:1258-65. http://www.ncbi.nlm.nih.gov/pubmed/9663484?dopt=AbstractPlus
55. Charles P, Elliott MJ, Davis D et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol. 1999;163:1521-8. http://www.ncbi.nlm.nih.gov/pubmed/10415055?dopt=AbstractPlus
56. Nakada MT, Tam SH, Woulfe DS et al. Neutralization of TNF by the antibody cA2 reveals differential regulation of adhesion molecule expression on TNF-activated endothelial cells. Cell Adhes Comm. 1998; 5:491-503.
57. Maini RN, Taylor PC, Paleolog E et al. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis. 1999;58(Suppl 1):56-60.
58. Gabay C, Kushner I. Acute-phase proteins and other systemic responses in inflammation. N Engl J Med. 1999; 340:448-54. http://www.ncbi.nlm.nih.gov/pubmed/9971870?dopt=AbstractPlus
59. Fox DA. Cytokine blockade as a new strategy to treat rheumatoid arthritis. Arch Intern Med. 2000; 160: 437-44. http://www.ncbi.nlm.nih.gov/pubmed/10695684?dopt=AbstractPlus
60. Lorenz HM; Grunke M; Hieronymus T et al. In vivo blockade of tumor necrosis factor-α in patients with rheumatoid arthritis: longterm effects after repeated infusion of chimeric monoclonal antibody cA2. J Rheumatol. 2000; 27:304-10. http://www.ncbi.nlm.nih.gov/pubmed/10685789?dopt=AbstractPlus
61. Taylor PC, Peters AM, Paleolog E et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis. Arth Rheum. 2000;43:38-47.
64. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999; 340:1398-405. http://www.ncbi.nlm.nih.gov/pubmed/10228190?dopt=AbstractPlus
68. Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol. 1999; 26(Suppl 57):16-21.
69. Baert FJ, D’Haens GR, Peeters M et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology. 1999; 116:22-8. http://www.ncbi.nlm.nih.gov/pubmed/9869598?dopt=AbstractPlus
71. Braegger CP, Nicholls S, Murch SH et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992;339:89-91. http://www.ncbi.nlm.nih.gov/pubmed/1345871?dopt=AbstractPlus
72. Centocor Inc, Malvern, PA: Personal communication.
84. Rezaian MM. Do infliximab and methotrexate act synergistically in the treatment of rheumatoid arthritis? Arthritis Rheum. 1999; 42:1779. Letter.
85. Maini RN, Feldmann M, Schaible T. Do infliximab and methotrexate act synergistically in the treatment of rheumatoid arthritis? Arthritis Rheum. 1999; 42:1779-81. Reply.
86. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn’s disease in children and adolescents. J Pediatr. 2000; 137:192-6. http://www.ncbi.nlm.nih.gov/pubmed/10931411?dopt=AbstractPlus
87. Kugathasan S, Werlin SL, Martinez A et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn’s disease. Am J Gastroenterol. 2000; 95:3189-94. http://www.ncbi.nlm.nih.gov/pubmed/11095340?dopt=AbstractPlus
89. Nikolaus S, Raedler A, Kuhbacher T et al. Mechanisms in failure of infliximab for Crohn’s disease. Lancet. 2000; 356:1475-9. http://www.ncbi.nlm.nih.gov/pubmed/11081530?dopt=AbstractPlus
90. Charles PJ, Smeenk RJT, De Jong J et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α. Arthritis Rheumatism. 2000; 43:2383-90. http://www.ncbi.nlm.nih.gov/pubmed/11083258?dopt=AbstractPlus
92. Puchner TC, Kugathasan S, Kelly KJ et al. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn’s disease patients with prior anaphylactic reaction. Inflamm Bowel Dis. 2001; 7:34-7. http://www.ncbi.nlm.nih.gov/pubmed/11233658?dopt=AbstractPlus
93. Hassard PV, Binder SW, Nelson V et al. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet’s disease: a case report. Gastroenterology. 2001; 120:995-9. http://www.ncbi.nlm.nih.gov/pubmed/11231954?dopt=AbstractPlus
96. Breese EJ, Michie CA, Nicholls SW et al. Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology. 1994; 106:1455-66. http://www.ncbi.nlm.nih.gov/pubmed/8194690?dopt=AbstractPlus
97. MacDonald TT, Hutchings P, Choy MY et al. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol. 1990; 81:301-5. http://www.ncbi.nlm.nih.gov/pubmed/2117510?dopt=AbstractPlus
102. Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behcet’s syndrome with infliximab. Rheumatology. 2001; 40:473-4. http://www.ncbi.nlm.nih.gov/pubmed/11312390?dopt=AbstractPlus
103. Elliott MJ, Woo P, Charles P et al. Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-α (cA2). Br J Rheumatol. 1997; 36:589-93. http://www.ncbi.nlm.nih.gov/pubmed/9189062?dopt=AbstractPlus
104. Gerloni V, Pontikaki I, Desiati F et al. Infliximab in the treatment of persistently active refractory juvenile idiopathic (chronic) arthritis: a short-term pilot study. American College of Rheumatology 64th Annual Scientific Meeting, Philadelphia, PA, Oct 30 to Nov 2 2000. Abstract No. 1139.
115. Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behcet’s syndrome with infliximab. Rheumatology. 2001; 40:473-4. http://www.ncbi.nlm.nih.gov/pubmed/11312390?dopt=AbstractPlus
116. Sfikakis PP, Theodossiadis PG, Katsiari CG et al. Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Lancet. 2001; 358:295-6. http://www.ncbi.nlm.nih.gov/pubmed/11498218?dopt=AbstractPlus
118. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab a tumor necrosis factor α neutralizing agent. N Engl J Med. 2001; 345:1098-104. http://www.ncbi.nlm.nih.gov/pubmed/11596589?dopt=AbstractPlus
123. Keane J, Gershon SK, Braun MM. Tuberculosis and treatment with infliximab. N Engl J Med. 2002; 346:625-6.
128. Lankarani KB. Mortality associated with infliximab. J Clin Gastroenterol. 2001; 33:255-6. http://www.ncbi.nlm.nih.gov/pubmed/11500623?dopt=AbstractPlus
135. de’ Clari F, Salani, I, Safwan E, et al. Sudden death in a patient without heart failure after a single infusion of 200 mg infliximab: does TNF-α have protective effects on the failing heart, or does infliximab have direct harmful cardiovascular effects? Circulation. 2002; 105:183e. From AHA web site. http://www.ahajournals.org
136. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002; 359:1541-49. http://www.ncbi.nlm.nih.gov/pubmed/12047962?dopt=AbstractPlus
137. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002; 359:1187-93. http://www.ncbi.nlm.nih.gov/pubmed/11955536?dopt=AbstractPlus
139. Chung ES, Packer M, Lo KH et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-(alpha), in patients with moderate-to-sever heart failure: results of the anti-TNF therapy against congestive heart failure (ATTCH) trial. Circulation. 2003. From AHA web site http://www.ahajournals.org
140. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004; 350:876-85. http://www.ncbi.nlm.nih.gov/pubmed/14985485?dopt=AbstractPlus
141. Fiocchi C. Closing fistulas in Crohn’s disease — Should the accent be on maintenance or safety? N Engl J Med. 2004; 350:934-6. Editorial.
142. Panaccione R, Fedorak RN, Aumais G et al. Canadian Association of Gastroenterology clinical practice guidelines: the use of infliximab in Crohn’s disease. Can J Gastroenterol. 2004; 18:503-8. http://www.ncbi.nlm.nih.gov/pubmed/15372114?dopt=AbstractPlus
145. St Clair EW, van der Heijde DM, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004; 50:3432-43. http://www.ncbi.nlm.nih.gov/pubmed/15529377?dopt=AbstractPlus
146. Wallis RS, Broder MS, Wong JY et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004; 38:1261-5. http://www.ncbi.nlm.nih.gov/pubmed/15127338?dopt=AbstractPlus
147. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353:2462-76. http://www.ncbi.nlm.nih.gov/pubmed/16339095?dopt=AbstractPlus
153. Ruperto N, Lovell DJ, Cuttica R et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007; 56:3096-106. http://www.ncbi.nlm.nih.gov/pubmed/17763439?dopt=AbstractPlus
154. Food and Drug Administration, Center for Drug Evaluation and Research. Information for healthcare professionals: Tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). FDA alert. Rockville MD; 2009 Aug 4. Available from FDA website. Accessed 2021 Sep 20. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/UCM070725
155. Food and Drug Administration, Center for Drug Evaluation and Research. FDA alert: Information for healthcare professionals Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab). Rockville MD: Food and Drug Administration; 2008 Sep 4. Available from FDA website. Accessed 2021 Sep 20. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174474.htm
157. Rennard SI, Fogarty C, Kelsen S et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 175:926-34. http://www.ncbi.nlm.nih.gov/pubmed/17290043?dopt=AbstractPlus
159. Food and Drug Administration. FDA drug safety communication: Drug labels for the tumor necrosis factor-alpha (TNFα) blockers now include warnings about infection with Legionella and Listeria bacteria. Rockville, MD; 2011 Sep 7. From FDA website. Accessed 2021 Sep 20. http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm
160. Food and Drug Administration. FDA drug safety communication: Safety review update on reports of hepatosplenic T-cell lymphoma in adolescents and young adults receiving tumor necrosis factor (TNF) blockers, azathioprine and/or mercaptopurine. Rockville, MD; 2011 Apr 14. From FDA website. Accessed 2021 Sep 20. http://www.fda.gov/Drugs/DrugSafety/ucm250913.htm
167. Pfizer, Inc. Inflectra (infliximab-dyyb) for IV injection prescribing information. New York, NY; 2021 Jun.
168. Food and Drug Administration, Center for Drug Evaluation and Research. Application number 125544Orig1s000: Summary review. From FDA website. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125544Orig1s000SumR.pdf
169. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Considerations in demonstrating interchangeability with a reference product guidance for industry. Guidance for industry. From FDA website. Accessed 2021 Nov. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-demonstrating-interchangeability-reference-product-guidance-industry
170. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Clinical pharmacology data to support a demonstration of biosimilarity to a reference product. Guidance for industry. From FDA website. Accessed 2021 Nov. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-data-support-demonstration-biosimilarity-reference-product
171. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. From FDA website. Accessed 2021 Nov. http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
172. Food and Drug Administration. FDA Purple Book Database of Licensed Biological Products. Rockville, MD. From FDA website. Accessed 2021 Nov 8. https://purplebooksearch.fda.gov
173. Yoo DH, Prodanovic N, Jaworski J et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017; 76:355-363. http://www.ncbi.nlm.nih.gov/pubmed/27130908?dopt=AbstractPlus
174. Yoo DH, Racewicz A, Brzezicki J et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther. 2016; 18:82. http://www.ncbi.nlm.nih.gov/pubmed/27038608?dopt=AbstractPlus
175. Park W, Hrycaj P, Jeka S et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013; 72:1605-12. http://www.ncbi.nlm.nih.gov/pubmed/23687259?dopt=AbstractPlus
176. Yoo DH, Hrycaj P, Miranda P et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013; 72:1613-20. http://www.ncbi.nlm.nih.gov/pubmed/23687260?dopt=AbstractPlus
177. Park W, Yoo DH, Jaworski J et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther. 2016; 18:25. http://www.ncbi.nlm.nih.gov/pubmed/26795209?dopt=AbstractPlus
188. Park W, Lee SJ, Yun J et al. Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study. Expert Rev Clin Immunol. 2015; 11 Suppl 1:S25-31. http://www.ncbi.nlm.nih.gov/pubmed/26395834?dopt=AbstractPlus
190. Food and Drug Administration, Center for Drug Evaluation and Research. Application number 125544Orig1s000: Chemistry review(s). From FDA website. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125544Orig1s000ChemR.pdf
191. Food and Drug Administration. Search orphan drug designations and approvals. From FDA website. Accessed 2021 Nov 26. http://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=175903
192. Park W, Yoo DH, Miranda P et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017; 76:346-354. http://www.ncbi.nlm.nih.gov/pubmed/27117698?dopt=AbstractPlus
193. Food and Drug Administration. Center for Drug Evaluation and Research. Application number 125544Orig1s000: Clinical pharmacology and biopharmaceutics review(s). From FDA website. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125544Orig1s000ClinPharmR.pdf
194. Organon LLC. Renflexis (infliximab-abda) for IV injection prescribing information. Jersey City, NJ; 2021 Jun
195. Amgen, Inc. Avsola (infliximab-axxq) for IV injection prescribing information. Thousand Oaks, CA; 2021 Sep.
196. Genovese MC, Sanchez-Burson J, Oh M, et al. Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis. Arthritis Res Ther. 2020;22(1):60.
197. Ye BD, Pesegova M, Alexeeva O, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019;393(10182):1699-1707.
198. Choe JY, Prodanovic N, Niebrzydowski J, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76(1):58-64.
199. Smolen JS, Choe JY, Prodanovic N, et al. Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. Rheumatology (Oxford). 2017;56(10):1771-1779.
200. Smolen JS, Choe JY, Prodanovic N, et al. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. Ann Rheum Dis. 2018;77(2):234-240.
201. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132(3):863-1166.
202. Hyams J, Walters TD, Crandall W, et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Curr Med Res Opin. 2011;27(3):651-662.
203. Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10(4):391-9.e1.
204. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582-591.
205. Braun J, Deodhar A, Dijkmans B, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum. 2008;59(9):1270-1278.
206. Braun J, Baraliakos X, Listing J, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis. 2008;67(3):340-345.
207. Giardina AR, Ferrante A, Ciccia F, et al. A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. Rheumatol Int. 2010;30(11):1437-1440.
208. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64(8):1150-1157.
209. Kavanaugh A, Krueger GG, Beutler A, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis. 2007;66(4):498-505.
210. van der Heijde D, Kavanaugh A, Gladman DD, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum. 2007;56(8):2698-2707.
211. Kavanaugh A, Antoni C, Krueger GG, et al. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis. 2006;65(4):471-477.
212. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52(4):1227-1236.
213. Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol. 2008;35(5):869-876.
214. Kavanaugh A, Antoni CE, Gladman D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis. 2006;65(8):1038-1043.
215. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367-1374.
216. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31.e1-31.e315.
217. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534-542.
218. Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol. 2006;154(6):1161-1168.
219. Feldman SR, Gordon KB, Bala M, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol. 2005;152(5):954-960.
220. de Vries AC, Thio HB, de Kort WJ, et al. A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study. Br J Dermatol. 2017;176(3):624-633.
221. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505-509.
222. Institute for Safe Medication Practices. List of confused drug names. 2019 Feb 28. Accessed 2021 Dec 1.
223. Food and Drug Administration, Center for Drug Evaluation and Research. Application number 761054Orig1s000: Summary review. From FDA website.
224. Food and Drug Administration, Center for Drug Evaluation and Research. Application number 761086Orig1s000: Multi-discipline review. From FDA website.
225. Celltrion, Inc. Zymfentra.(infliximab-dyyb) injection, for subcutaneous use prescribing information. Jersey City, NJ; 2023 Oct.
2000. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical guideline: management of Crohn disease in adults. Am J Gastroenterol. 2018;113(4):481-517.
2001. Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn disease. Gastroenterology. 2021;160(7):2496-2508.
2002. Nguyen GC, Loftus EV Jr, Hirano I, et al. American Gastroenterological Association Institute guideline on the management of Crohn disease after surgical resection. Gastroenterology. 2017;152(1):271-275.
2003. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924-939.
2004. Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599-1613.
2005. Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5-32.
2006. Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75(5):811-818.
2007. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072.
2008. Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432-470.
2009. Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445-1486.
2010. Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161-201.
2011. Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073-1113.
2012. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945-1960.
2015. Fuller MK. Pediatric inflammatory bowel disease: special considerations. Surg Clin North Am. 2019;99(6):1177-1183.
2016. Grover Z, Alex G. Management of inflammatory bowel disease in children: it is time for an individualised approach. J Paediatr Child Health. 2020;56(11):1677-1684.
2017. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-1583.
2018. Ko CW, Singh S, Feuerstein JD, et al. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019;156(3):748-764.
2019. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450-1461.
2020. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384-413.
Frequently asked questions
- What are the new drugs for rheumatoid arthritis (RA)?
- What is the mechanism of action of infliximab?
- What is the difference between Inflectra and Remicade?
- What is the difference between Renflexis and Remicade?
- What are the new drugs for plaque psoriasis?
- How many biosimilars have been approved in the United States?
- What is the difference between Ixifi and Remicade?
More about infliximab
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (284)
- Side effects
- Dosage information
- During pregnancy
- Drug class: antirheumatics
- Breastfeeding
- En español
Patient resources
Professional resources
Other brands
Remicade, Inflectra, Renflexis, Avsola, Zymfentra